Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006381 · ClinicalTrials.gov registry record · Phase 2
Celecoxib and Trastuzumab in Treating Women With Metastatic Breast Cancer
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00006381: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00006381 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006381, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Celecoxib may be effective in preventing the further development of cancer. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining trastuzumab with celecoxib may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining celecoxib and trastuzumab in treating women who have metastatic breast cancer that has not responded to previous trastuzumab.
Interventions
- BIOLOGICAL trastuzumab
- DRUG celecoxib
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-06 |
| Est. Completion | 2004-02 |
| Phase | Phase 2 |
What the finished NCT00006381 record still lists
NCT00006381 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which trastuzumab is the first listed.
NCT00006381 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00006381 about?
NCT00006381 is a clinical study titled "Celecoxib and Trastuzumab in Treating Women With Metastatic Breast Cancer". RATIONALE: Celecoxib may be effective in preventing the further development of cancer. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining trastuzumab with celecoxib may kill more tu...
What is the current status of trial NCT00006381?
This trial is currently completed. It is a Phase 2 study. The study started on 2000-06. Estimated completion is 2004-02.
What interventions are being tested in trial NCT00006381?
The interventions under investigation include: trastuzumab (BIOLOGICAL), celecoxib (DRUG).
Who is sponsoring clinical trial NCT00006381?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia